Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Leases (2019 - 2025)

Historic Current Leases for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2025 value amounting to $10.9 million.

  • Theravance Biopharma's Current Leases rose 16010.49% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 16010.49%. This contributed to the annual value of $10.7 million for FY2024, which is 17305.63% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Current Leases is $10.9 million, which was up 16010.49% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Current Leases ranged from a high of $10.9 million in Q3 2025 and a low of $503000.0 during Q4 2021
  • In the last 5 years, Theravance Biopharma's Current Leases had a median value of $4.2 million in 2024 and averaged $5.5 million.
  • As far as peak fluctuations go, Theravance Biopharma's Current Leases tumbled by 9490.22% in 2021, and later soared by 130361.27% in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's Current Leases stood at $503000.0 in 2021, then surged by 1242.54% to $6.8 million in 2022, then tumbled by 41.91% to $3.9 million in 2023, then skyrocketed by 173.06% to $10.7 million in 2024, then rose by 1.89% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $10.9 million for Q2 2025, and $10.8 million during Q1 2025.